{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:51:38Z","timestamp":1791834698245,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T00:00:00Z","timestamp":1455062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T00:00:00Z","timestamp":1455062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s40265-016-0545-8","type":"journal-article","created":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T17:45:38Z","timestamp":1455126338000},"page":"567-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":293,"title":["Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent"],"prefix":"10.1007","volume":"76","author":[{"given":"George G.","family":"Zhanel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Zelenitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala","family":"Gorityala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe R. S.","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walkty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred S.","family":"Gin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,10]]},"reference":[{"issue":"1","key":"545_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/00003495-200464010-00005","volume":"64","author":"GG Zhanel","year":"2004","unstructured":"Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63\u201388.","journal-title":"Drugs."},{"key":"545_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.2011.06354.x","volume":"1241","author":"ML Nelson","year":"2011","unstructured":"Nelson ML, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci. 2011;1241:17\u201332.","journal-title":"Ann N Y Acad Sci."},{"key":"545_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-0711-12-22","volume":"12","author":"M Bassetti","year":"2013","unstructured":"Bassetti M, Merelli M, Temperoni C, et al. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob. 2013;12:22.","journal-title":"Ann Clin Microbiol Antimicrob."},{"issue":"3","key":"545_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00018-009-0172-6","volume":"67","author":"M Thaker","year":"2010","unstructured":"Thaker M, Spanogiannopoulos P, Wright GD. The tetracycline resistome. Cell Mol Life Sci. 2010;67(3):419\u201331.","journal-title":"Cell Mol Life Sci."},{"issue":"5","key":"545_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1515\/hsz-2013-0292","volume":"395","author":"F Nguyen","year":"2014","unstructured":"Nguyen F, Starosta AL, Arenz S, et al. Tetracycline antibiotics and resistance mechanisms. Biol Chem. 2014;395(5):559\u201375.","journal-title":"Biol Chem."},{"issue":"2","key":"545_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1021\/jm201465w","volume":"55","author":"XY Xiao","year":"2012","unstructured":"Xiao XY, Hunt DK, Zhou J, et al. Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem. 2012;55(2):597\u2013605.","journal-title":"J Med Chem."},{"issue":"2","key":"545_CR7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1021\/jm201467r","volume":"55","author":"RB Clark","year":"2012","unstructured":"Clark RB, Hunt DK, He M, et al. Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy. J Med Chem. 2012;55(2):606\u201322.","journal-title":"J Med Chem."},{"issue":"5","key":"545_CR8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1021\/op4000219","volume":"17","author":"M Ronn","year":"2013","unstructured":"Ronn M, Zhu Z, Hogan PC, et al. Process R&D of eravacycline: the first fully synthetic fluorocycline in clinical development. Org Process Res Dev. 2013;17(5):838\u201345.","journal-title":"Org Process Res Dev."},{"issue":"11","key":"545_CR9","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1517\/13543784.2014.965253","volume":"23","author":"M Bassetti","year":"2014","unstructured":"Bassetti M, Righi E. Eravacycline for the treatment of intra-abdominal infections. Expert Opin Investig Drugs. 2014;23(11):1575\u201384.","journal-title":"Expert Opin Investig Drugs."},{"issue":"5","key":"545_CR10","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1128\/AAC.06187-11","volume":"56","author":"TH Grossman","year":"2012","unstructured":"Grossman TH, Starosta AL, Fyfe C, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012;56(5):2559\u201364.","journal-title":"Antimicrob Agents Chemother."},{"issue":"11","key":"545_CR11","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","volume":"57","author":"JA Sutcliffe","year":"2013","unstructured":"Sutcliffe JA, O\u2019Brien W, Fyfe C, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57(11):5548\u201358.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"545_CR12","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1128\/AAC.01614-13","volume":"58","author":"JS Solomkin","year":"2014","unstructured":"Solomkin JS, Ramesh MK, Cesnauskas G, et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58(4):1847\u201354.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"545_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","volume":"65","author":"I Chopra","year":"2001","unstructured":"Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65(2):232\u201360.","journal-title":"Microbiol Mol Biol Rev."},{"key":"545_CR14","first-page":"258","volume-title":"Wilson and Gisvold\u2019s textbook of organic medicinal and pharmaceutical chemistry","author":"JM Beale","year":"2011","unstructured":"Beale JM. Antibacterial Antibiotics. In: Beale JM, Block JH, editors. Wilson and Gisvold\u2019s textbook of organic medicinal and pharmaceutical chemistry. 12th ed. Baltimore: Lippincott Williams & Wilkins; 2011. p. 258\u2013329.","edition":"12"},{"key":"545_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/B978-1-4557-0282-4.00039-3","volume-title":"Pharmacology","author":"GM Brenner","year":"2013","unstructured":"Brenner GM, Stevens CW. Inhibitors of bacterial protein synthesis. In: Brenner GM, Stevens CW, editors. Pharmacology. 4th ed. Philadelphia: Elsevier Saunders; 2013. p. 408\u201316.","edition":"4"},{"issue":"2","key":"545_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.femsle.2005.02.034","volume":"245","author":"MC Roberts","year":"2005","unstructured":"Roberts MC. Update on acquired tetracycline resistance genes. FEMS Microbiol Lett. 2005;245(2):195\u2013203.","journal-title":"FEMS Microbiol Lett."},{"issue":"11","key":"545_CR17","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1128\/AAC.00308-08","volume":"52","author":"KA Kazimierczak","year":"2008","unstructured":"Kazimierczak KA, Rincon MT, Patterson AJ, et al. A new tetracycline efflux gene, tet(40), is located in tandem with tet(O\/32\/O) in a human gut firmicute bacterium and in metagenomic library clones. Antimicrob Agents Chemother. 2008;52(11):4001\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"7","key":"545_CR18","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1128\/AEM.02511-06","volume":"73","author":"SA Thompson","year":"2007","unstructured":"Thompson SA, Maani EV, Lindell AH, et al. Novel tetracycline resistance determinant isolated from an environmental strain of Serratia marcescens. Appl Environ Microbiol. 2007;73(7):2199\u2013206.","journal-title":"Appl Environ Microbiol."},{"issue":"12","key":"545_CR19","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1128\/AAC.00640-08","volume":"52","author":"MG Brown","year":"2008","unstructured":"Brown MG, Mitchell EH, Balkwill DL. Tet 42, a novel tetracycline resistance determinant isolated from deep terrestrial subsurface bacteria. Antimicrob Agents Chemother. 2008;52(12):4518\u201321.","journal-title":"Antimicrob Agents Chemother."},{"issue":"9","key":"545_CR20","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1093\/jac\/dkt127","volume":"68","author":"Y You","year":"2013","unstructured":"You Y, Hilpert M, Ward MJ. Identification of Tet45, a tetracycline efflux pump, from a poultry-litter-exposed soil isolate and persistence of tet(45) in the soil. J Antimicrob Chemother. 2013;68(9):1962\u20139.","journal-title":"J Antimicrob Chemother."},{"issue":"1","key":"545_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jac\/dks351","volume":"68","author":"PJ Warburton","year":"2013","unstructured":"Warburton PJ, Ciric L, Lerner A, et al. TetAB46, a predicted heterodimeric ABC transporter conferring tetracycline resistance in Streptococcus australis isolated from the oral cavity. J Antimicrob Chemother. 2013;68(1):17\u201322.","journal-title":"J Antimicrob Chemother."},{"issue":"3","key":"545_CR22","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/AAC.04809-14","volume":"59","author":"M Abdallah","year":"2015","unstructured":"Abdallah M, Olafisoye O, Cortes C, et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015;59(3):1802\u20135.","journal-title":"Antimicrob Agents Chemother."},{"key":"545_CR23","unstructured":"Zhanel GG, Adam H, Baxter M, et al. Activity of eravacycline and comparators against 3,174 pathogens isolated from Canadian hospitals: CANWARD; 2014."},{"key":"545_CR24","unstructured":"Hackel M, Bouchillon S, Biedenbach D, et al. Comparative analysis of eravacycline (TP-434) by Broth microdilution and disk diffusion [abstract no. E-1180 plus poster]. 53rd annual interscience conference on antimicrobial agents and chemotherapy; 10\u201313 Sep 2013; Denver."},{"key":"545_CR25","unstructured":"Sutcliffe J, O\u2019Brien W, Achorn C, et al. In vitro activity of fluorocycline TP-434 against panels of recent bacterial clinical isolates [abstract no. F1-2158 plus poster]. 50th annual interscience conference on antimicrobial agents and chemotherapy; 12\u201315 Sep 2010; Boston."},{"key":"545_CR26","unstructured":"Hunt D, Xiao X, Clark R, et al. TP-434 is a novel broad-spectrum fluorocycline [abstract no. F1-2157 plus poster]. 50th annual interscience conference on antimicrobial agents and chemotherapy; 12\u201315 Sep 2010; Boston."},{"issue":"1","key":"545_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1586\/14787210.4.1.9","volume":"4","author":"GG Zhanel","year":"2006","unstructured":"Zhanel GG, Karlowsky JA, Rubinstein E, et al. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther. 2006;4(1):9\u201325.","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"1","key":"545_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1586\/14787210.3.1.23","volume":"3","author":"GG Zhanel","year":"2005","unstructured":"Zhanel GG, Johanson C, Embil JM, et al. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther. 2005;3(1):23\u201339.","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"3","key":"545_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1586\/14787210.5.3.365","volume":"5","author":"A Gin","year":"2007","unstructured":"Gin A, Dilay L, Karlowsky JA, et al. Piperacillin-tazobactam: a beta-lactam\/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007;5(3):365\u201383.","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"Suppl 1","key":"545_CR30","doi-asserted-by":"publisher","first-page":"i7","DOI":"10.1093\/jac\/dkt022","volume":"68","author":"GG Zhanel","year":"2013","unstructured":"Zhanel GG, Adam HJ, Baxter MR, et al. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. J Antimicrob Chemother. 2013;68(Suppl 1):i7\u201322.","journal-title":"J Antimicrob Chemother."},{"key":"545_CR31","unstructured":"Morrisey I, Sutcliffe J, Hackel M, Hawser S. Assessment of eravacycline against 3467 recent gram-positive bacteria including multidrug resistant isolates collected from 2013\u20132014 [abstract no. C-563 plus poster]. 55th annual interscience conference on antimicrobial agents and chemotherapy; 17\u201321 Sep 2015; San Diego."},{"key":"545_CR32","unstructured":"Fyfe C, Grossman T, O\u2019Brien W, et al. The novel broad-spectrum fluorocycline TP-434 is active against MDR Gram-negative pathogens [abstract no P1149 plus poster]. 21st European Congress of Clinical Microbiology and Infectious Diseases\/27th International Congress of Chemotherapy; 7\u201310 May 2011; Milan."},{"key":"545_CR33","unstructured":"Grossman TH, O\u2019Brien W, Fyfe C, et al. Eravacycline is potent against third generation cephalosporin- and carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and has isolate-specific bactericidal activity [abstract no. C-1374 plus poster]. 54th annual interscience conference on antimicrobial agents and chemotherapy; 5\u20139 Sep 2014; Washington."},{"key":"545_CR34","unstructured":"Kerstein K, Fyfe C, Sutcliffe JA, et al. Eravacycline (TP-434) is active against susceptible and multidrug-resistant Neisseria gonorrhoeae [abstract no. E-1181 plus poster]. 53rd annual interscience conference on antimicrobial agents and chemotherapy; 10\u201313 Sep 2013; Denver."},{"key":"545_CR35","doi-asserted-by":"crossref","unstructured":"Morrisey I, Sutcliffe J, Hackel M, Hawser S. Activity of eravacycline against anaerobic bacteria from europe collected in 2013\u20132014 [abstract no. 784 plus poster]. ID Week; 7\u201311 Oct 2015; San Diego.","DOI":"10.1093\/ofid\/ofv133.501"},{"key":"545_CR36","unstructured":"McDermott LA, Jacobus NV, Snydman DR, et al. In vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates [abstract no. 1417 plus poster]. ID Week; 17\u201321 Sep 2015; San Diego."},{"key":"545_CR37","unstructured":"Dubois J, Dubois M, Martel JF, et al. In vitro activity of fluorocyclines against Legionella pneumophilia [abstract no. F1-2159 plus poster]. 50th annual interscience conference on antimicrobial agents and chemotherapy; 12\u201315 Sep 2010; Boston."},{"key":"545_CR38","unstructured":"Hershfield J, Howlett A, Schweizer HP, et al. Eravacycline is potent against category A and B pathogens [abstract no. 114G plus poster]. ASM biodefense and emerging diseases; 25\u201327 Feb 2013; Washington."},{"key":"545_CR39","unstructured":"Sutcliffe J, Selden J, Gooldy M, et al. Eravacycline is efficacious in a Francisella tularensis-infected cynomolgus monkey model [abstract no. 094G plus poster]. American Society of Microbiology Biodefense and Emerging Diseases; 27\u201329 Jan 2014; Washington."},{"issue":"4","key":"545_CR40","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1128\/AAC.04967-14","volume":"59","author":"TH Grossman","year":"2015","unstructured":"Grossman TH, O\u2019Brien W, Kerstein KO, et al. Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Antimicrob Agents Chemother. 2015;59(4):2446\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"545_CR41","unstructured":"Leighton A, Zupanets I, Bezugla N, et al. Broad-spectrum fluorocycline TP-434 has oral bioavailability in humans [abstract no. P 1509 plus poster]. 21st European Congress of Clinical Microbiology and Infectious Diseases\/27th International Congress of Chemotherapy; 7\u201310 May 2011; Milan."},{"key":"545_CR42","unstructured":"Horn PT, Sutcliffe JA, Walpole SM, et al. Pharmacokinetics, safety and tolerability of a novel fluorocycline, TP-434 following multiple dose administration. [abstract no. 603 plus poster]. 49th Annual Infectious Diseases Society of America; 20\u201323 Oct 2011; Boston."},{"key":"545_CR43","unstructured":"Singh RSP, Falcao NMS, Sutcliffe J, et al. Plasma Protein binding of eravacycline in mouse, rat, rabbit, cynomolgus monkey, African green monkey and human using microdialysis [abstract no. A-015 plus poster]. 53rd annual interscience conference on antimicrobial agents and chemotherapy; 10\u201313 Sep 2013; Denver."},{"key":"545_CR44","unstructured":"Yue CS, Sutcliffe JA, Colucci P, et al. Population pharmacokinetics modeling of TP-434, a novel fluorocycline, following single and multiple dose administration [abstract no. A1-028 plus poster]. 50th annual interscience conference on antimicrobial agents and chemotherapy; 12\u201315 Sep; 2010 Boston."},{"key":"545_CR45","unstructured":"Pfizer. Tygacil: product monograph. 2014; http:\/\/www.pfizer.ca\/sites\/g\/files\/g10017036\/f\/201410\/TYGACIL_PM_E_168980_17Jan2014.pdf. Accessed 30 July 2015."},{"key":"545_CR46","unstructured":"Sutcliffe J, Grossman T, Ronn M, et al. TP-434 has potential to treat complicated urinary tract infections (cUTI) [abstract no. F1-1858 plus poster]. 51th annual interscience conference on antimicrobial agents and chemotherapy; 17\u201320 Sep 2011; Chicago."},{"key":"545_CR47","unstructured":"Tsai L, March A, Lloyd K, et al. Results of the lead-in study on the safety and efficacy of eravacycline versus levofloxacin in complicated urinary tract infection [abstract no. 0198]. 25th European Congress of Clinical Microbiology and Infectious Diseases; 25\u201328 Apr; 2015 Copenhagen."},{"issue":"4","key":"545_CR48","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1128\/AAC.02036-13","volume":"58","author":"KP Connors","year":"2014","unstructured":"Connors KP, Housman ST, Pope JS, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother. 2014;58(4):2113\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"545_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","volume":"26","author":"WA Craig","year":"1998","unstructured":"Craig WA. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1\u201312.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"545_CR50","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1128\/AAC.00813-07","volume":"52","author":"JA Passarell","year":"2008","unstructured":"Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008;52(1):204\u201310.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"545_CR51","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1128\/AAC.01084-06","volume":"51","author":"AK Meagher","year":"2007","unstructured":"Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother. 2007;51(6):1939\u201345.","journal-title":"Antimicrob Agents Chemother."},{"key":"545_CR52","unstructured":"Weiss WJ, Pulse M, Renick P, et al. Efficacy of fluorocyclines TP-434 in the neutropenic thigh infection model is predicted by AUC\/MIC [abstract no. F1-2164 plus poster]. 50th Annual interscience conference on antimicrobial agents and chemotherapy; 12\u201315 Sep 2010; Boston."},{"issue":"5","key":"545_CR53","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1128\/AAC.04354-14","volume":"59","author":"TH Grossman","year":"2015","unstructured":"Grossman TH, Murphy TM, Slee AM, et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015;59(5):2567\u201371.","journal-title":"Antimicrob Agents Chemother."},{"key":"545_CR54","unstructured":"Sutcliffe J, Selden J, Radcliff A, et al. Eravacycline protects in a Bacillus anthracis-infected New Zealand white rabbit treatment model [abstract no. P0109 plus poster]. 24th European Congress of Clinical Microbiology and Infectious Diseases; 10\u201313 May 2014; Barcelona."},{"key":"545_CR55","unstructured":"Murphy T, Slee A, Sutcliffe J. TP-434 is Highly efficacious in animal models of infection [abstract no. F1-2161 plus poster]. 50th annual interscience conference on antimicrobial agents and chemotherapy (ICAAC), 12\u201315, Sep 2010; Boston."},{"key":"545_CR56","unstructured":"Solomkin J, Evans SD, Slepavicius A, et al. Results of IGNITE 1: a phase 3 study to evaluate the efficacy and safety of eravacycline versus ertapenem in complicated intra-abdomial infections [abstract no. 4174]. 25th European Congress of Clinical Microbiology and Infectious Diseases; 25\u201328 Apr; 2015 Copenhagen."},{"key":"545_CR57","first-page":"2011","volume-title":"The authority on drug interactions","author":"Drug Interaction Facts","year":"2012","unstructured":"Drug Interaction Facts. The authority on drug interactions. St. Louis: Lippincott Williams & Wilkins; 2012. p. 2011."},{"key":"545_CR58","volume-title":"Drug interactions analysis and management","author":"PD Hansten","year":"2013","unstructured":"Hansten PD, Horn JR. Drug interactions analysis and management. 8th ed. St. Louis: Lippincott Williams & Wilkins; 2013.","edition":"8"},{"key":"545_CR59","volume-title":"Compendium of pharmaceuticals and specialties","author":"Canadian Pharmacists Association","year":"2015","unstructured":"Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmacists Association; 2015."},{"key":"545_CR60","unstructured":"Drug information handbook. 22nd ed. Hudson: Lexi-Comp Inc.; 2013."},{"key":"545_CR61","unstructured":"Christ D, Sutcliffe J. TP-434 is metabolicallly stable and has low potential for drug\u2013drug interactions [abstract no. F1-2162 plus poster]. 50th Annual interscience conference on antimicrobial agents and chemotherapy; 12\u201315 Sep 2010; Boston."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0545-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-016-0545-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0545-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0545-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:05:26Z","timestamp":1744700726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-016-0545-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,10]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0545-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,10]]},"assertion":[{"value":"10 February 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Zhanel has received research grants from Tetraphase Pharmaceuticals Inc. Drs. Cheung, Adam, Zelenitsky, Golden, Schweizer, Gorityala, Lagac\u00e9-Wiens, Walkty, Gin, Hoban and Karlowsky have no conflicts of interest to declare.The authors are grateful to Tetraphase Pharmaceuticals for their assistance with literature retrieval and an unrestricted research grant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}